A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom

Autor: Paul Mitchell, Adrian Skelly, Alberto Ferreira, Robert L. Johnston, Hans-Joachim Carius, F Milnes
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Vascular Endothelial Growth Factor A
Visual acuity
genetic structures
Databases
Factual
Angiogenesis Inhibitors
Pro re nata regimen
0302 clinical medicine
Electronic Health Records
Pharmacology (medical)
030212 general & internal medicine
Original Research
Medicine(all)
Aged
80 and over
Treatment regimen
General Medicine
Choroidal neovascularization
Treatment Outcome
Cohort
Intravitreal Injections
Female
medicine.symptom
Drug Monitoring
medicine.drug
Neovascular age-related macular degeneration
medicine.medical_specialty
Drug Administration Schedule
03 medical and health sciences
Internal medicine
Ophthalmology
Ranibizumab
medicine
Humans
Anti-vascular endothelial growth factor
Aged
business.industry
Australia
Retrospective cohort study
Macular degeneration
medicine.disease
eye diseases
Rheumatology
Real-world data
Choroidal Neovascularization
United Kingdom
Treat-and-extend regimen
030221 ophthalmology & optometry
Wet Macular Degeneration
business
Zdroj: Advances in Therapy
ISSN: 1865-8652
0741-238X
Popis: Introduction Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss among persons aged 65 years and older. Anti-vascular endothelial growth factor (anti-VEGF) treatment is the recommended standard of care. The current study compares the effectiveness of ranibizumab in routine clinical practice in two countries that generally apply two different treatment regimens, treat-and-extend (T&E) in Australia or pro re nata (PRN) in the UK. Methods This retrospective, comparative, non-randomised cohort study is based on patients’ data from electronic medical record (EMR) databases in Australia and the UK. Treatment regimens were defined based on location, with Australia as a proxy for analysing T&E and UK as a proxy for analysing PRN. The study included patients with a diagnosis of nAMD who started treatment with ranibizumab between January 2009 and July 2014. A total of 647 eyes of 570 patients in Australia and 3187 eyes of 2755 patients in the UK with complete 12-months follow-up were analysed. Results Baseline patient characteristics were comparable between the two cohorts. After 1 year of treatment, T&E-treated eyes achieved higher mean (±SE) visual acuity (VA) gains (5.00 ± 0.54 letters [95% confidence interval (CI) 3.93–6.06]) than PRN-treated eyes [3.04 ± 0.24 letters (95% CI 2.57–3.51); difference in means 2.07 ± 0.69 (95% CI 0.73–3.41), p
Databáze: OpenAIRE
Externí odkaz: